Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US-9157916-B2 · Oct 13, 2015 · US
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US10018638B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10018638-B2 |
| Application number | US-201715606877-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 26, 2017 |
| Priority date | Sep 20, 2001 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for determining a dosage of a therapeutic anti-CD20 antibody for treating B cell hyperproliferative disease, the method comprising testing a sample from a human to measure the level of soluble CD20, and determining the dosage of the therapeutic anti-CD20 antibody according to the level of soluble CD20. 2. The method of claim 1 , wherein said sample is selected from the group consisting of plasma, serum, and cell lysate. 3. The method of claim 1 , wherein said therapeutic anti-CD20 antibody is Rituximab. 4. The method of claim 1 , wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocyte leukemia, multiple myeloma, hairy cell leukemia, prolymphocytic leukemia, or lymphoma. 5. The method of claim 4 , wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia. 6. The method of claim 1 , further comprising administering said therapeutic anti-CD20 antibody to said human. 7. The method of claim 3 , further comprising administering said Rituximab to said human.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10018638B2 cover?
- The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexe…
- Who is the assignee on this patent?
- Univ Texas
- What technology area does this patent fall under?
- Primary CPC classification G01N33/564. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).